26 results on '"Kesavan, Murali"'
Search Results
2. Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma
3. Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
4. Impaired humoral and cellular response to primary COVID ‐19 vaccination in patients less than 2 years after allogeneic bone marrow transplant
5. Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome
6. Myeloid Toxicity of Radionuclide Cancer Therapy
7. Long‐term efficacy and safety of chemotherapy‐free first‐line iodine‐131‐rituximab radioimmunotherapy of follicular lymphoma
8. Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET
9. Haematologic Toxicity of Radioimmunotherapy and Radiopeptide Treatment of Cancer
10. Additional file 1 of A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma
11. Myeloid Toxicity of Radionuclide Cancer Therapy.
12. Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
13. Long‐term efficacy and safety of chemotherapy‐free first‐line iodine‐131‐rituximab radioimmunotherapy of follicular lymphoma.
14. Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
15. Novel Targets and Therapies in T Cell Lymphoma
16. CNS Relapse Risk in Consecutive R-CHOP/R-Mini-CHOP-Treated Elderly DLBCL Is Low, with High Risk Particularly Apparent in Those with CNS IPI 5-6 and/or Renal/Adrenal Involvement
17. Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice
18. Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy
19. Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
20. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience
21. A case of acquired high molecular weight kininogen deficiency
22. The prognostic impact of CD7 expression of leukaemic blasts in de novo intermediate cytogenetic risk acute myeloid leukaemia
23. Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up
24. Hematological Toxicity of Combined Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up.
25. The prognostic impact of CD7 expression of leukaemic blasts in de novointermediate cytogenetic risk acute myeloid leukaemia
26. Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.